Identification of predictive biomarkers for cytokine release syndrome after chimeric antigen receptor T-cell therapy for acute lymphoblastic leukemia

Cancer Discovery

Volumn 6, Issue 6, 2016, Pages 664-679

  Teachey, David T ^a,b,c   Lacey, Simon F ^b,c   Shaw, Pamela A ^b   Melenhorst, J Joseph ^b,c   Maude, Shannon L ^a,b,c   Frey, Noelle ^b,c   Pequignot, Edward ^b,c   Gonzalez, Vanessa E ^b,c   Chen, Fang ^b,c   Finklestein, Jeffrey ^b,c   Barrett, David M ^a,b,c   Weiss, Scott L ^b   Fitzgerald, Julie C ^b   Berg, Robert A ^b   Aplenc, Richard ^a,b,c   Callahan, Colleen ^a   Rheingold, Susan R ^a,b,c   Zheng, Zhaohui ^b,c   Rose John, Stefan ^d   White, Jason C ^e   Nazimuddin, Farzana ^b,c   Wertheim, Gerald ^b,c   Levine, Bruce L ^b,c   June, Carl H ^b,c   Porter, David L ^b,c   Grupp, Stephan A ^a,b,c   more..

^a CHILDREN S HOSPITAL OF PHILADELPHIA   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

^c UNIVERSITY OF PENNSYLVANIA   (United States)

^d UNIVERSITY OF KIEL   (Germany)

^e FORT BELVOIR COMMUNITY HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; BIOCHEMICAL MARKER; C REACTIVE PROTEIN; CD19 ANTIGEN; CHIMERIC ANTIGEN RECEPTOR; CREATININE; FERRITIN; GAMMA INTERFERON; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 6; INTERLEUKIN 8; LACTATE DEHYDROGENASE; MACROPHAGE INFLAMMATORY PROTEIN; MONOCYTE CHEMOTACTIC PROTEIN 1; TOCILIZUMAB; BIOLOGICAL MARKER; CYTOKINE; LYMPHOCYTE ANTIGEN RECEPTOR; MONOCLONAL ANTIBODY;

ACUTE LYMPHOBLASTIC LEUKEMIA; ADOLESCENT; ADULT; AGED; ARTICLE; CHILD; CYTOKINE RELEASE SYNDROME; CYTOKINE STORM; HEMOPHAGOCYTIC SYNDROME; HUMAN; HUMAN TISSUE; HYPOTENSION; IMMUNOTHERAPY; INFLAMMATION; MACROPHAGE ACTIVATION SYNDROME; MAJOR CLINICAL STUDY; REAL TIME POLYMERASE CHAIN REACTION; T CELL THERAPY; UREA NITROGEN BLOOD LEVEL; ADVERSE EFFECTS; BIOLOGICAL THERAPY; COMPLICATION; FEMALE; GENETICS; IMMUNOLOGY; MALE; METABOLISM; MIDDLE AGED; PHENOTYPE; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; PRESCHOOL CHILD; PROCEDURES; PROGNOSIS; RECEIVER OPERATING CHARACTERISTIC; SECRETION (PROCESS); SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME; TUMOR LYSIS SYNDROME; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTIGENS, CD19; BIOMARKERS; CELL- AND TISSUE-BASED THERAPY; CHILD; CHILD, PRESCHOOL; CYTOKINES; FEMALE; HUMANS; IMMUNOTHERAPY; MALE; MIDDLE AGED; PHENOTYPE; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; PROGNOSIS; RECEPTORS, ANTIGEN, T-CELL; ROC CURVE; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME; TUMOR LYSIS SYNDROME; YOUNG ADULT;

EID: 85011955241     PISSN: 21598274     EISSN: 21598290     Source Type: Journal    
DOI: 10.1158/2159-8290.CD-16-0040     Document Type: Article

References (35)

1. Grupp SA, Kalos M, Barrett D, Aplenc R, Porter DL, Rheingold SR, et al. Chimeric antigen receptor-modified T cells for acute lymphoid leukemia. N Engl J Med 2013;368:1509-18.
2. Maude SL, Frey N, Shaw PA, Aplenc R, Barrett DM, Bunin NJ, et al. Chimeric antigen receptor T cells for sustained remissions in leukemia. N Engl J Med 2014;371:1507-17.
3. Davila ML, Riviere I, Wang X, Bartido S, Park J, Curran K, et al. Efficacy and toxicity management of 19-28z CAR T cell therapy in B cell acute lymphoblastic leukemia. Sci Transl Med 2014;6:224ra25.
4. Lee DW, Kochenderfer JN, Stetler-Stevenson M, Cui YK, Delbrook C, Feldman SA, et al. T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial. Lancet 2015;385:517-28.
5. Porter DL, Levine BL, Kalos M, Bagg A, June CH. Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia. N Engl J Med 2011;365:725-33.
6. Klinger M, Brandl C, Zugmaier G, Hijazi Y, Bargou RC, Topp MS, et al. Immunopharmacologic response of patients with B-lineage acute lymphoblastic leukemia to continuous infusion of T cellengaging CD19/CD3-bispecific BiTE antibody blinatumomab. Blood 2012;119:6226-33.
7. Teachey DT, Rheingold SR, Maude SL, Zugmaier G, Barrett DM, Seif AE, et al. Cytokine release syndrome after blinatumomab treatment related to abnormal macrophage activation and ameliorated with cytokine-directed therapy. Blood 2013;121:5154-7.
8. Allen CE, Yu X, Kozinetz CA, McClain KL. Highly elevated ferritin levels and the diagnosis of hemophagocytic lymphohistiocytosis. Pediatr Blood Cancer 2008;50:1227-35.
9. Switala JR, Hendricks M, Davidson A. Serum ferritin is a cost-effective laboratory marker for hemophagocytic lymphohistiocytosis in the developing world. J Pediatr Hematol Oncol 2012;34:e89-92.
10. Janka G, zur Stadt U. Familial and acquired hemophagocytic lymphohistiocytosis. Hematology Am Soc Hematol Educ Program 2005: 82-8.
11. Xu XJ, Tang YM, Song H, Yang SL, Xu WQ, Zhao N, et al. Diagnostic accuracy of a specific cytokine pattern in hemophagocytic lymphohis-tiocytosis in children. J Pediatr 2012;160:984-90.
12. Tang Y, Xu X, Song H, Yang S, Shi S, Wei J, et al. Early diagnostic and prognostic significance of a specific Th1/Th2 cytokine pattern in children with haemophagocytic syndrome. Br J Haematol 2008;143:84-91.
13. Tamura K, Kanazawa T, Tsukada S, Kobayashi T, Kawamura M, Morikawa A. Increased serum monocyte chemoattractant protein-1, macrophage inflammatory protein-1beta, and interleukin-8 concentrations in hemophagocytic lymphohistiocytosis. Pediatr Blood Cancer 2008;51:662-8.
14. Takada H, Takahata Y, Nomura A, Ohga S, Mizuno Y, Hara T. Increased serum levels of interferon-gamma-inducible protein 10 and monokine induced by gamma interferon in patients with haemophagocytic lymphohistiocytosis. Clin Exp Immunol 2003;133: 448-53.
15. Osugi Y, Hara J, Tagawa S, Takai K, Hosoi G, Matsuda Y, et al. Cytokine production regulating Th1 and Th2 cytokines in hemophagocytic lymphohistiocytosis. Blood 1997;89:4100-3.
16. Henter JI, Elinder G, Soder O, Hansson M, Andersson B, Andersson U. Hypercytokinemia in familial hemophagocytic lymphohistiocytosis. Blood 1991;78:2918-22.
17. Bhattacharyya M, Ghosh MK. Hemophagoctic lymphohistiocytosis-recent concept. J Assoc Physicians India 2008;56:453-7.
18. Koehne G, Hasan A, Doubrovina E, Prockop S, Tyler E, Wasilewski G, et al. Immunotherapy with donor T cells sensitized with overlapping pentadecapeptides for treatment of persistent cytomegalovirus infection or viremia. Biol Blood Marrow Transplant 2015;21:1663-78.
19. Briso EM, Dienz O, Rincon M. Cutting edge: soluble IL-6R is produced by IL-6R ectodomain shedding in activated CD4 T cells. J Immunol 2008;180:7102-6.
20. Calabrese LH, Rose-John S. IL-6 biology: implications for clinical targeting in rheumatic disease. Nat Rev Rheumatol 2014;10: 720-7.
21. Nishimoto N, Terao K, Mima T, Nakahara H, Takagi N, Kakehi T. Mechanisms and pathologic significances in increase in serum interleukin-6 (IL-6) and soluble IL-6 receptor after administration of an anti-IL-6 receptor antibody, tocilizumab, in patients with rheumatoid arthritis and Castleman disease. Blood 2008;112:3959-64.
22. Garbers C, Aparicio-Siegmund S, Rose-John S. The IL-6/gp130/ STAT3 signaling axis: recent advances towards specific inhibition. Curr Opin Immunol 2015;34:75-82.
23. Rose-John S. IL-6 trans-signaling via the soluble IL-6 receptor: importance for the pro-inflammatory activities of IL-6. Int J Biol Sci 2012;8:1237-47.
24. Rose-John S, Heinrich PC. Soluble receptors for cytokines and growth factors: generation and biological function. Biochem J 1994;300: 281-90.
25. Uno K, Yoshizaki K, Iwahashi M, Yamana J, Yamana S, Tanigawa M, et al. Pretreatment prediction of individual rheumatoid arthritis patients’ response to anti-cytokine therapy using serum cytokine/chemokine/soluble receptor biomarkers. PLoS ONE 2015; 10:e0132055.
26. Maney SK, McIlwain DR, Polz R, Pandyra AA, Sundaram B, Wolff D, et al. Deletions in the cytoplasmic domain of iRhom1 and iRhom2 promote shedding of the TNF receptor by the protease ADAM17. Sci Signal 2015;8:ra109.
27. Burska A, Boissinot M, Ponchel F. Cytokines as biomarkers in rheumatoid arthritis. Mediators Inflamm 2014;2014:545493.
28. Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, et al. Current concepts in the diagnosis and management of cytokine release syndrome. Blood 2014;124:188-95.
29. Porter DL, Hwang WT, Frey NV, Lacey SF, Shaw PA, Loren AW, et al. Chimeric antigen receptor T cells persist and induce sustained remissions in relapsed refractory chronic lymphocytic leukemia. Sci Transl Med 2015;7:303ra139.
30. Borowitz MJ, Devidas M, Hunger SP, Bowman WP, Carroll AJ, Carroll WL, et al. Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia and its relationship to other prognostic factors: a Children’s Oncology Group study. Blood 2008;111:5477-85.
31. Weir EG, Cowan K, LeBeau P, Borowitz MJ. A limited antibody panel can distinguish B-precursor acute lymphoblastic leukemia from normal B precursors with four color flow cytometry: implications for residual disease detection. Leukemia 1999;13:558-67.
32. Holm S. A simple sequentially rejective multiple test procedure. Scand J Stat 1979;6:70.
33. Berdat PA, Wehrle TJ, Kung A, Achermann F, Sutter M, Carrel TP, et al. Age-specific analysis of normal cytokine levels in healthy infants. Clin Chem Lab Med 2003;41:1335-9.
34. Lilic D, Cant AJ, Abinun M, Calvert JE, Spickett GP. Cytokine production differs in children and adults. Pediatr Res 1997;42:237-40.
35. Kleiner G, Marcuzzi A, Zanin V, Monasta L, Zauli G. Cytokine levels in the serum of healthy subjects. Mediators Inflamm 2013;2013: 434010.